Clinical research study to evaluate the effectiveness and safety of a potential oral medication for subjects with metastatic castration resistant prostate cancer
NCT03395197
ABOUT THIS STUDY

Study Website
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Who can take part in the study?
You may be able to join the TALAPRO-2 study if you meet the following criteria:
- you have a diagnosis of metastatic castration-resistant prostate cancer
- you are 18 years of age or older
- you are willing to provide saliva, blood and tumor tissue samples for genetic testing
- you are otherwise in reasonably good health
You will not be able to take part in the study if you have received:
- systemic cancer treatment (treatment that enters the bloodstream to reach cells all over the body), not including androgen deprivation therapy and first-generation anti-androgens, since your metastatic castration-resistant prostate cancer diagnosis
- treatment with enzalutamide, apalutamide or darolutamide (and certain other therapies used in the treatment of prostate cancer that your doctor will be able to check for you)
- treatment with platinum-based chemotherapy within 6 months (from the last dose)
There are other requirements for participation in the study. The study doctor will be able to explain these to you.
NEED INFO?
All other inquiries: Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Warsaw,
- Chandler, Arizona
- Gilbert, Arizona
- Gilbert, Arizona
- Gilbert, Arizona
- Mesa, Arizona
- Mesa, Arizona
- Scottsdale, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Beverly Hills, California
- Chula Vista, California
- Chula Vista, California
- Glendale, California
- Greenbrae, California
- La Mesa, California
- Loma Linda, California
- Loma Linda, California
- Long Beach, California
- Los Angeles, California
- Orange, California
- Palo Alto, California
- Rancho Mirage, California
- Rancho Mirage, California
- San Diego, California
- San Diego, California
- San Diego, California
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Denver, Colorado
- Danbury, Connecticut
- New Milford, Connecticut
- Norwalk, Connecticut
- Altamonte Springs, Florida
- Bonita Springs, Florida
- Bradenton, Florida
- Brandon, Florida
- Cape Coral, Florida
- Celebration, Florida
- Clearwater, Florida
- Daytona Beach, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Kissimmee, Florida
- Lakeland, Florida
- Largo, Florida
- Lecanto, Florida
- Naples, Florida
- New Port Richey, Florida
- Ocala, Florida
- Orange City, Florida
- Orlando, Florida
- Orlando, Florida
- Orlando, Florida
- Port Charlotte, Florida
- Saint Petersburg, Florida
- Sarasota, Florida
- Sarasota, Florida
- Spring Hill, Florida
- Tampa, Florida
- Tavares, Florida
- The Villages, Florida
- Venice, Florida
- Venice, Florida
- Vero Beach, Florida
- Wellington, Florida
- West Palm Beach, Florida
- Winter Park, Florida
- Athens, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Fayetteville, Georgia
- Newnan, Georgia
- Newnan, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Hinsdale, Illinois
- Hinsdale, Illinois
- Zion, Illinois
- Jeffersonville, Indiana
- Iowa City, Iowa
- Fairway, Kansas
- Westwood, Kansas
- Louisville, Kentucky
- New Orleans, Louisiana
- Baltimore, Maryland
- Saint Louis, Missouri
- Billings, Montana
- Billings, Montana
- Omaha, Nebraska
- Omaha, Nebraska
- Omaha, Nebraska
- Omaha, Nebraska
- Belleville, New Jersey
- Voorhees, New Jersey
- Albuquerque, New Mexico
- Farmington, New Mexico
- Bronx, New York
- Poughkeepsie, New York
- Syracuse, New York
- Cincinnati, Ohio
- Middleburg Heights, Ohio
- Oklahoma City, Oklahoma
- Clackamas, Oregon
- Clackamas, Oregon
- Hillsboro, Oregon
- Newberg, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Springfield, Oregon
- Altoona, Pennsylvania
- Bethel Park, Pennsylvania
- Greensburg, Pennsylvania
- Lancaster, Pennsylvania
- Monroeville, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Seneca, Pennsylvania
- Uniontown, Pennsylvania
- Washington, Pennsylvania
- Myrtle Beach, South Carolina
- Chattanooga, Tennessee
- Chattanooga, Tennessee
- Cleveland, Tennessee
- Harrogate, Tennessee
- Jefferson City, Tennessee
- Knoxville, Tennessee
- Knoxville, Tennessee
- Morristown, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- El Paso, Texas
- Houston, Texas
- Round Rock, Texas
- Temple, Texas
- Farmington, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- South Jordan, Utah
- Fairfax, Virginia
- Fairfax, Virginia
- Seattle, Washington
- Seattle, Washington
- Madison, Wisconsin
- Madison, Wisconsin
- Pergamino, Buenos Aires
- Rosario, Santa FE
- Caba,
- Caba,
- Cordoba,
- Cordoba,
- Camperdown, New South Wales
- Darlinghurst, New South Wales
- Port Macquarie, New South Wales
- Auchenflower, Queensland
- Auchenflower, Queensland
- Brisbane, Queensland
- Chermside, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- Southport, Queensland
- Melbourne, Victoria
- North Melbourne, Victoria
- Brasschaat,
- Gent,
- Gent,
- Kortrijk,
- Ottignies,
- Yvoir,
- Rio de Janeiro, RJ
- Rio de Janeiro, RJ
- Rio de Janeiro, RJ
- Ijui, RS
- Lajeado, RS
- Porto Alegre, RS
- Porto Alegre, RS
- Porto Alegre, RS
- Barretos, SP
- Santo Andre, SP
- Santo Andre, SP
- Sao Paulo, SP
- Sao Paulo, SP
- Sao Paulo, SP
- Sao Paulo, SP
- São Paulo, SP
- Calgary, Alberta
- Ottawa, Ontario
- Chicoutimi, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Santiago, Metropolitana
- Temuco, Region DE LA Araucania
- Temuco, Region DE LA Araucania
- Temuco, Region DE LA Araucania
- Vina del Mar, Valparaiso
- Vina del Mar, Valparaiso
- Hefei, Anhui
- Beiijng, Beijing
- Beijing, Beijing
- Beijing, Beijing
- Fuzhou, Fujian
- Xiamen, Fujian
- Wuhan, Hubei
- Wuhan, Hubei
- Nanjing, Jiangsu
- Suzhou, Jiangsu
- Wuxi, Jiangsu
- Nanchang, Jiangxi
- Shanghai, Shanghai
- Shanghai, Shanghai
- Shanghai, Shanghai
- Xi'an, Shanxi
- Chengdu, Sichuan
- Kunming, Yunnan
- Hangzhou, Zhejiang
- Hangzhou, Zhejiang
- Ningbo, Zhejiang
- Chongqing,
- Shanghai,
- Shanghai,
- Shanghai,
- Tianjin,
- Hradec Kralove,
- Ostrava-Poruba,
- Pardubice,
- Pardubice,
- Praha 10,
- Usti nad Labem,
- Helsinki,
- Helsinki,
- Helsinki,
- Kempele,
- Kuopio,
- Kuopio,
- Oulu,
- Tampere,
- Turku,
- Bayonne,
- Bayonne,
- Bordeaux Cedex,
- Bordeaux,
- LA ROCHE SUR YON cedex 9,
- Le Mans,
- Le Mans,
- Lyon CEDEX 08,
- Montpellier cedex 5,
- Paris Cedex 15,
- Paris,
- Paris,
- Strasbourg,
- Strasbourg,
- Suresnes Cedex,
- Suresnes,
- VILLEJUIF cedex,
- Erlangen, Bayern
- Duesseldorf,
- Erlangen,
- Hamburg,
- Heidelberg,
- Kirchheim,
- Muenster,
- Nuertingen,
- Ravensburg,
- Reutlingen,
- Weiden,
- Budapest,
- Budapest,
- Budapest,
- Budapest,
- Debrecen,
- Debrecen,
- Pecs,
- Haifa,
- Jerusalem,
- Petah Tikva,
- Tel Aviv,
- Bologna, BO
- Cremona, CR
- Meldola, FC
- Terni, TN
- Trento, TN
- Orbassano, TO
- Brescia,
- Napoli,
- Napoli,
- Nagoya, Aichi
- Hirosaki, Aomori
- Kashiwa, Chiba
- Matsuyama, Ehime
- Kure, Hiroshima
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Kanazawa, Ishikawa
- Yokohama, Kanagawa
- Yokosuka, Kanagawa
- Osaka-shi, Osaka
- Osakasayama, Osaka
- Suita, Osaka
- Hamamatsu, Shizuoka
- Meguro-ku, Tokyo
- Shinjuku-ku, Tokyo
- Chiba,
- Fukuoka,
- Kagoshima,
- Kumamoto,
- Tokushima,
- Yamagata,
- Yamagata,
- Goyang-si, Gyeonggi-do
- Goyang-si, Gyeonggi-do
- Busan,
- Daegu,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Tauranga, BAY OF Plenty
- Christchurch, Canterbury
- Hamilton, Waikato
- Auckland,
- Auckland,
- Gralum,
- Gralum,
- Lorenskog,
- Oslo,
- Oslo,
- Trondheim,
- Trondheim,
- Arequipa,
- Lima,
- Lima,
- Lima,
- Lima,
- Brzozow,
- Gdynia,
- Konin,
- Otwock,
- Warszawa,
- Braga,
- Coimbra,
- Lisboa,
- Lisboa,
- Porto,
- Porto,
- Port Elizabeth, Eastern CAPE
- Johannesburg, Gauteng
- Johannesburg, Gauteng
- Johannesburg, Gauteng
- Cape Town, Western CAPE
- George, Western CAPE
- Kraaifontein, Cape Town, Western CAPE
- Santiago de Compostela, A Coruna
- Elche, Alicante
- L'Hospitalet de Llobregat, Barcelona
- L'Hospitalet de Llobregat, Barcelona
- Sabadell, Barcelona
- El Palmar, Murcia
- Barcelona,
- Barcelona,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Goteborg,
- Stockholm,
- Umeå,
- Umeå,
- Plymouth, Devon
- Bebington, Wirral
- Cornwall,
- Glasgow,
- Liverpool,
- London,
- London,
- London,
- Oxford,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | ||||||
Official Title ICMJE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | ||||||
Brief Summary | This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide. | ||||||
Detailed Description | Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double-blind. Primary Purpose: Treatment
| ||||||
Condition ICMJE | mCRPC | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 1037 | ||||||
Original Estimated Enrollment ICMJE | 444 | ||||||
Estimated Study Completion Date ICMJE | November 25, 2024 | ||||||
Estimated Primary Completion Date | August 22, 2021 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria: Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell features Asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be < 4). For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1). Surgically or medically castrated, with serum testosterone ? 50 ng/dL (? 1.73 nmol/L) at screening. Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan. Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:
Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory. Eastern Cooperative Oncology Group (ECOG) performance status ? 1. Life expectancy ? 12 months as assessed by the investigator. Able to swallow the study drug and have no known intolerance to study drugs or excipients. Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential. Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug. Evidence of a personally signed and dated informed consent document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Exclusion Criteria: Any prior systemic cancer treatment initiated in in the non metastatic CRPC and mCRPC disease state. Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation. Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer. Prior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose). Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2). Treatment with any investigational agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2). Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2). Current use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2). Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2). Clinically significant cardiovascular disease Significant renal dysfunction as defined by any of the following laboratory abnormalities: ? Renal: eGFR < 30 mL/min/1.73 m2 by the MDRD equation (available via www.mdrd.com). Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening. Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:
Absolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening). Known or suspected brain metastasis or active leptomeningeal disease. Symptomatic or impending spinal cord compression or cauda equina syndrome. Any history of myelodysplastic syndrome, acute myeloid leukemia, or prior malignancy except any of the following:
Gastrointestinal disorder affecting absorption. Fertile male subjects who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for 4 months after the last dose of investigational product. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study. Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization (Part 2). | ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Norway, Peru, Poland, Portugal, South Africa, Spain, Sweden, United Kingdom, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03395197 | ||||||
Other Study ID Numbers ICMJE | C3441021 2017-003295-31 ( EudraCT Number ) TALAPRO-2 ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Astellas Pharma Inc | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |